多发性骨髓瘤感染预防共识指南与推荐:国际骨髓瘤工作组报告
国际骨髓瘤学会召集36名全球专家,综述现有文献与指南,针对新兴治疗背景下多发性骨髓瘤感染风险与感染并发症预防提出共识推荐。最佳预防策略包括疫苗接种、抗菌药物预防、感染控制措施及小部分患者免疫球蛋白替代,但目前尚无普遍接受的感染预防指南。
要点
- 感染是多发性骨髓瘤患者发病和死亡的首位原因,风险随疾病全程累积。
- 最佳预防策略包括疫苗接种、抗菌药物预防、感染控制措施及小部分患者免疫球蛋白替代。
- 目前尚无普遍接受的感染预防指南,本共识由36名全球专家制定。
核心结论
- 感染是多发性骨髓瘤患者发病和死亡的首位原因,预防感染至关重要,本共识为新兴治疗背景下感染并发症的预防提供推荐。
研究设计与样本
- 国际骨髓瘤学会召集36名具有全球代表性的专家组成专家组,综述现有文献与当前指南并形成共识声明。
主要发现
- 感染风险由疾病、治疗及宿主相关因素的累积效应所致,且在整个疾病过程中累积。
- 最佳预防策略包括针对常见病原体的疫苗接种、抗菌药物预防、感染控制措施及小部分患者的免疫球蛋白替代。
关键数值与推荐
- 原文未报告具体推荐条款、推荐等级或关键数值。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.
引用
- Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022. PMID: 35114152. doi:10.1016/S2352-3026(21)00283-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。